Status:
RECRUITING
Safety of Serum for Post-Inflammatory on Hyperpigmentation Skin
Lead Sponsor:
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
Conditions:
Healthy
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
This study aims to investigate the safety of serum product containing low dose of alpha hydroxy acid (AHA) i.e. 1% Glycolic acid and Lactic acid and Polyglutamate acid derivatives (PGA) for post-infla...
Eligibility Criteria
Inclusion
- Malaysian from 18 to 40 years old.
- Participants with post-inflammatory hyperpigmentation (PIH).
Exclusion
- Participant with known systemic or skin disease and any underlying medical illness
- Pregnant, breastfeeding women or planned pregnancy during the study period.
- Had reported history of dermatologic conditions (i.e. Atopic dermatitis, psoriasis) or known allergies to any ingredients that may be found in the product.
- Had any cosmetic procedures such as Botox, laser and light treatment, facial surgery, chemical peel and any procedures that may improve skin texture 1 month before the study.
- Had history of taking isotretinoin for the past 6 or 12 month and AHA (alpha hydroxyl acids) containing products or any other products for treating hyperpigmentation skin or melasma 1 month prior to study.
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2025
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05998200
Start Date
July 1 2023
End Date
October 30 2025
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
Petaling Jaya, Selangor, Malaysia, 47810